Last reviewed · How we verify
Bismuth Potassium Citrate
Bismuth potassium citrate forms a protective coating on the gastric mucosa and has antimicrobial activity against Helicobacter pylori.
Bismuth potassium citrate forms a protective coating on the gastric mucosa and has antimicrobial activity against Helicobacter pylori. Used for Peptic ulcer disease, Helicobacter pylori infection, Gastritis.
At a glance
| Generic name | Bismuth Potassium Citrate |
|---|---|
| Also known as | Bismuth, Bitnal, Bismuth potassium citrate, colloidal bismuth tartrate capsule, Denol |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Bismuth salt / mucoprotective agent |
| Target | Helicobacter pylori (bacterial target); gastric mucosa (protective mechanism) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Bismuth compounds work by creating a barrier that protects the stomach lining from acid and pepsin while simultaneously exhibiting bactericidal effects against H. pylori. The citrate formulation enhances solubility and bioavailability. This dual action makes it effective for treating peptic ulcer disease and H. pylori infection.
Approved indications
- Peptic ulcer disease
- Helicobacter pylori infection
- Gastritis
Common side effects
- Darkening of stool
- Nausea
- Constipation
- Abdominal discomfort
Key clinical trials
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer (PHASE2)
- Drug Interaction Study on Linaprazan Glurate Capsules (PHASE1)
- Rescue Therapy for Helicobacter Pylori Infection (PHASE4)
- Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bismuth Potassium Citrate CI brief — competitive landscape report
- Bismuth Potassium Citrate updates RSS · CI watch RSS
- Shanghai Jiao Tong University School of Medicine portfolio CI